Rxcurve
HCPCS J3357 · per 1 MG

Ustekinumab sub cu inj, 1 mg

This code is not in the latest file (4Q26). It was last listed in 1Q25.

Payment limit per 1 MG, by effective quarter, 1Q21 to 1Q25. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J3357

No NDCs mapped to this code in the 4Q26 crosswalk.

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
1Q25 $155.883 −$4.03 1 MG Ustekinumab sub cu inj, 1 mg v1, posted December 19, 2025
4Q24 $159.913 +$1.755 1 MG Ustekinumab sub cu inj, 1 mg v1, posted June 11, 2025
3Q24 $158.158 +$5.593 1 MG Ustekinumab sub cu inj, 1 mg v1, posted June 11, 2025
2Q24 $152.565 −$1.39 1 MG Ustekinumab sub cu inj, 1 mg v1, posted March 11, 2025
1Q24 $153.955 +$2.497 1 MG Ustekinumab sub cu inj, 1 mg v1, posted December 19, 2024
4Q23 $151.458 +$3.811 1 MG Ustekinumab sub cu inj, 1 mg v1, posted October 10, 2024
3Q23 $147.647 −$6.121 1 MG Ustekinumab sub cu inj, 1 mg v1, posted June 5, 2024
2Q23 $153.768 −$1.234 1 MG Ustekinumab sub cu inj, 1 mg v1, posted February 23, 2024
1Q23 $155.002 −$7.847 1 MG Ustekinumab sub cu inj, 1 mg v1, posted December 6, 2023
4Q22 $162.849 −$11.842 1 MG Ustekinumab sub cu inj, 1 mg v1, posted June 22, 2023
3Q22 $174.691 +$8.376 1 MG Ustekinumab sub cu inj, 1 mg v1, posted June 9, 2023
2Q22 $166.315 −$4.504 1 MG Ustekinumab sub cu inj, 1 mg v1, posted December 14, 2022
1Q22 $170.819 −$5.95 1 MG Ustekinumab sub cu inj, 1 mg v1, posted June 8, 2022
4Q21 $176.769 +$4.30 1 MG Ustekinumab sub cu inj, 1 mg v1, posted June 2, 2022
3Q21 $172.469 +$1.291 1 MG Ustekinumab sub cu inj, 1 mg v1, posted June 2, 2022
2Q21 $171.178 −$8.938 1 MG Ustekinumab sub cu inj, 1 mg v1, posted March 1, 2022
1Q21 $180.116 – 1 MG Ustekinumab sub cu inj, 1 mg v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files